There are currently 118 active clinical trials seeking participants for Pancreatic Cancer research studies. The states with the highest number of trials for Pancreatic Cancer participants are California, New York, Illinois and Texas.
Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable or Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma
NCT03704662
Recruiting
Patients are randomized into two arms. Arm A patients will receive Stereotactic Body Radiation Therapy (SBRT) and Arm B patients with receive conventional concurrent chemotherapy and radiation therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/22/2025
Locations: Froedtert Hospital & Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Pancreatic Cancer
Register for Updates
EUS RFA for Treatment of Pancreatic Ductal Adenocarcinoma (PDAC)
NCT05723107
Recruiting
This is a single arm study in the treatment of pancreatic ductal adenocarcinoma (PDAC). The investigators propose to test the tolerability of chemotherapy plus endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) using the RF Electrode in patients receiving palliative second or third line therapy for unresectable non-metastatic pancreatic cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/21/2025
Locations: Tisch Hospital, New York, New York
Conditions: Pancreatic Cancer
Register for Updates
Switch Maintenance in Pancreatic
NCT05419479
Recruiting
This study is being done to test the safety and effectiveness of combining domvanalimab (AB154), zimberelimab (AB122), and APX005M with pancreatic cancer that has spread to other parts of body. This research study involves immunotherapy. Immunotherapy triggers the body's immune system to fight cancer cells. The names of the study drugs involved in this study are: * Domvanalimab (also known as AB154) * Zimberelimab (also known as AB122) * APX005M
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/20/2025
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Pancreatic Cancer, Adenocarcinoma of the Pancreas, Squamous Cell Carcinoma of Pancreas, Adenosquamous Carcinoma of the Pancreas
Register for Updates
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
NCT02584244
Recruiting
The overall goal of this feasibility study is to assess the initial safety and efficacy of LUM015 in ex vivo far-red imaging of colorectal, pancreatic, and esophageal cancers (adenocarcinoma) using the LUM Imaging System.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/13/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Colorectal Cancer, Pancreatic Cancer, Esophageal Cancer, Gastric Cancer
Register for Updates
Preliminary Evaluation of Screening for Pancreatic Cancer in Patients with Inherited Genetic Risk
NCT02478892
Recruiting
The study is a prospective, observational study evaluating the utility of endoscopic ultrasound or MRI for the identification of preneoplastic and neoplastic pancreatic lesions in patients at high risk for pancreatic cancer, specifically those with BRCA1/2, ATM, or PALB2 mutations.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/10/2025
Locations: Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Pancreatic Cancer
Register for Updates
ZN-c3 + Gemcitabine in Pancreatic Cancer
NCT06015659
Recruiting
This study is being done to test the safety and effectiveness of combining ZN-c3 and Gemcitabine in participants with pancreatic cancer. The names of the study drugs involved in this study are: * ZN-c3 (a small molecule inhibitor of the WEE1 tyrosine kinase) * Gemcitabine (a nucleoside metabolic inhibitor)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/09/2025
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Advanced Pancreatic Adenocarcinoma, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma
Register for Updates
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
NCT05497531
Recruiting
This is a prospective pilot protocol investigating whether ctDNA detection be improved by sampling the cancer draining vein versus the standard practice of sampling from a peripheral vein in patients who are undergoing biopsies for hepatobiliary and pancreatic cancers.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/07/2025
Locations: Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, California
Conditions: Hepatobiliary Cancer, Pancreatic Cancer, Hepatocellular Carcinoma, Cholangiocarcinoma, Ampullary Cancer, Pancreatic Carcinoma
Register for Updates
Study of EGFRBi Armed Fresh PBMC in Metastatic or Unresectable Pancreatic Cancer
NCT06479239
Recruiting
The purpose of this study is to understand the safety and estimate the efficacy of combining anti-cluster of differentiation 3 (CD3) x anti-Epidermal Growth Factor Receptor (EGFR) bispecific antibody fresh peripheral blood mononuclear cells (EGFR FPBMC) for patients with relapsed and/or refractory pancreas cancer. Participants receive 8 weekly doses and then 8 more doses every 2 weeks of EGFR FPBMC by intravenous infusion.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/02/2024
Locations: University of Virginia, Charlottesville, Virginia
Conditions: Pancreas Cancer, Pancreatic Cancer
Register for Updates
GENOCARE: a Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care
NCT05391126
Recruiting
This is a prospective, randomized study designed to compare genotype-guided dosing to usual care in patients with pancreas cancer and colorectal cancer who are UGT1A1 intermediate metabolizers (\*1/\*28) (heterozygotes) and usual UGT metabolizers (\*1/\*1). All patients will be assessed for UGT1A1 genotype at screening and those with intermediate or usual UGT1A1 genotypes (\*1/\*28, \*1/\*1) will be randomized to genotype-guided dosing versus usual care.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/27/2024
Locations: University of Kentucky, Lexington, Kentucky
Conditions: Colorectal Cancer, Pancreatic Cancer
Register for Updates
Mass Response of Tumor Cells As a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
NCT05461430
Recruiting
The primary objective of this study, sponsored by Travera Inc. in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using isolated tumor cells from various specimen formats including malignant fluids such as pleural effusions and ascites, core needle biopsies, fine needle aspirates, or resections.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/21/2024
Locations: xCures, Oakland, California
Conditions: Pleural Effusion, Malignant, Ascites, Malignant, Carcinoma, Carcinoma, Hepatocellular, Carcinoma, Renal Cell, Carcinoma, Renal, Carcinoma, Small Cell, Carcinoma, Non-Small-Cell Lung, Carcinoma, Pancreatic Ductal, Carcinoma, Neuroendocrine, Carcinoma, Thymic, Carcinoma, Pancreatic, Carcinoma Breast, Carcinoma, Ovarian, Carcinoma Bladder, Carcinoma of Unknown Primary, Carcinoma of the Head and Neck, Carcinoma of the Oropharynx, Carcinoma of the Larynx, Carcinoma of the Bladder, Carcinoma of Esophagus, Carcinoma of the Nasopharynx, Carcinoma of the Penis, Carcinoma of the Cervix, Carcinoma of the Anus, Carcinoma of the Vulva, Carcinoma of the Appendix, Carcinoma of the Oral Cavity, Cholangiocarcinoma, Melanoma, Mesothelioma, Pancreatic Cancer
Register for Updates
Video Education With Result Dependent dIsclosure
NCT05225428
Recruiting
The overall study objective of this trial study is to identify and evaluate strategies to improve the accessibility of the video education with result dependent disclosure (VERDI) model, increasingly utilized as a pre-genetic testing (pretest) education alternative in clinical practice, to better serve a more diverse patient population at risk for hereditary cancers.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/20/2024
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Genetic Testing, Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Colorectal Cancer, Renal Cancer, Melanoma, Sarcoma
Register for Updates
Pancreatic Cancer Adaptive Neoadjuvant Chemotherapy Trial
NCT03322995
Recruiting
This is an open-label, phase II study in patients with resectable and borderline resectable pancreas cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/19/2024
Locations: Froedtert & the Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Pancreatic Cancer
Register for Updates